Table 3 Off-label use of tocilizumab in pediatric patients with non-JIA rheumatic diseases except Takayasu arteritis and JIA-associated uveitis

Juvenile SLE

13

Improved arthritis and inflammatory markers Reduction of GC dose

400 mg/month

No

[21]

Juvenile dermatomyositis

12

Improved arthritis

8 mg/kg/4 weeks

No

[28]

Takayasu arteritis

3–16

Improved symptoms and inflammatory marker Reduction of GC dose No FDG uptake

8 mg/kg/3–4 weeks

No

[34,35,36,37,38]

Juvenile localized scleroderma

6–13

Improved disease activity and inhibition of progression

≥30 kg: 8 mg/kg

< 30 kg: 12 mg/kg every 4 weeks

No

[47, 48]

Autoimmune encephalitis

10, 12, 15

Improved neurological symptoms without recurrence

8–12 mg/kg/4 weeks

No

[51]

Kawasaki’s disease

1–8

Improved symptoms and inflammatory markers

8 mg/kg once

Giant coronary artery aneurysm (2)

[55]

JIA-associated uveitis

8–38

Improved visual acuity

Reduction of GC dose

8 mg/kg/4 weeks

Thrombocytopenia (1), pneumonia, thrombocytopenia, and hemolytic anemia (1), viral conjunctivitis and bullous impetigo (1)

[57, 58, 60, 62]

Multicentric Castleman’s disease

1–16

Sustained remission

8 mg/kg/2 weeks

10 mg/kg three times

8 mg/kg/2 weeks

Herpes zoster (1)

[64,65,66]

Amyloid A amyloidosis

19, 26, 29

Improved symptoms and inflammatory markers

8 mg/kg/2–4 weeks

No

[68, 69]

Cytokine release syndrome (CRS)

7–16

Improved symptoms and inflammatory markers

8 mg/kg 1–3 times

No

[72, 73]

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS)

4

Improved symptoms and inflammatory markers

8 mg/kg/month

No

[74]

H syndrome (PHID)

3–19

Improved symptoms and inflammatory markers

IV: 8 mg/kg

SQ: 10.8–12 mg/kg every 2 weeks

No

[76, 77]

Undifferentiated autoinflammatory disease with interstitial pneumonitis

15

Improved symptoms and reduction of ground-glass opacity on CT

8 mg/kg/month

No

[78]